Publications by authors named "Edward Brink"

Claim this Profile
R
Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies.
Pekka Kallunki, Florence Sotty, Katarina Willén, Michal Lubas, Laurent David, Edward N van den Brink

NPJ Parkinsons Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models.
Kristel Kemper, Ellis Gielen, Peter Boross, Mischa Houtkamp, Theo S Plantinga, Edward N van den Brink

Life Sci Alliance· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Alexander Muik, Elena Garralda, Isil Altintas, Friederike Gieseke, Ravit Geva, Edward N van den Brink

Cancer Discov· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DuoHexaBody-CD37, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies.
Simone C Oostindie, Hilma J van der Horst, Laurens P Kil, Kristin Strumane, Marije B Overdijk, Edward N van den Brink

Blood Cancer J· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Patrick J Engelberts, Ida H Hiemstra, Bart de Jong, Danita H Schuurhuis, Joyce Meesters, Edward N van den Brink

EBioMedicine· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.
Bart E C G de Goeij, Matthias Peipp, Simone de Haij, Edward N van den Brink, Christian Kellner

MAbs· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.
Mark Throsby, Edward van den Brink, Mandy Jongeneelen, Leo L M Poon, Philippe Alard

PLoS One· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
Jan ter Meulen, Edward N van den Brink, Leo L M Poon, Wilfred E Marissen, Cynthia S W Leung

PLoS Med· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents.
Eric E Mast, Harold S Margolis, Anthony E Fiore, Edward W Brink, Susan T Goldstein

MMWR Recomm Rep· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.
Edward N van den Brink, Jan Ter Meulen, Freek Cox, Mandy A C Jongeneelen, Alexandra Thijsse

J Virol· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets.
Jan ter Meulen, Alexander B H Bakker, Edward N van den Brink, Gerrit J Weverling, Byron E E Martina

Lancet· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS preparedness checklist for state and local health officials.
Richard S Hopkins, Lara Misegades, James Ransom, Leigh Lipson, Edward W Brink

Emerg Infect Dis· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adolescent immunizations. are we ready for a new wave?
Donna Rickert, Adeline Deladisma, Hussain Yusuf, Francisco Averhoff, Edward Brink

Am J Prev Med· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of factor VIII inhibitors in a haemophilia A patient with an Arg593-->Cys mutation using phage display.
Wendy S Bril, Ellen A M Turenhout, Paul H P Kaijen, Edward N van den Brink, Maria M W Koopman

Br J Haematol· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two classes of germline genes both derived from the V(H)1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII.
Edward N van den Brink, Wendy S Bril, Ellen A M Turenhout, Marleen Zuurveld, Niels Bovenschen

Blood· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis